Home » Stocks » Novavax

Novavax, Inc. (NVAX)

Stock Price: $157.17 USD 1.30 (0.83%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $172.12 +14.95 (9.51%) Aug 4, 6:17 PM

Stock Price Chart

Key Info

Market Cap 9.36B
Revenue (ttm) 18.06M
Net Income (ttm) -115.34M
Shares Out 58.69M
EPS (ttm) -3.83
PE Ratio n/a
Forward PE 34.97
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $157.17
Previous Close $155.87
Change ($) 1.30
Change (%) 0.83%
Day's Open 156.34
Day's Range 150.28 - 157.30
Day's Volume 10,604,575
52-Week Range 3.54 - 159.97

More Stats

Market Cap 9.36B
Enterprise Value 9.44B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.69M
Float 54.38M
EPS (basic) -4.09
EPS (diluted) -3.83
FCF / Share -2.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.50M
Short Ratio 0.98
Short % of Float 13.90%
Beta 1.49
PE Ratio n/a
Forward PE 34.97
P/FCF Ratio n/a
PS Ratio 518.63
PB Ratio n/a
Revenue 18.06M
Operating Income -103.26M
Net Income -115.34M
Free Cash Flow -110.30M
Net Cash -76.30M
Net Cash / Share -1.28
Gross Margin -527.11%
Operating Margin -571.83%
Profit Margin -638.80%
FCF Margin -610.84%
ROA -25.55%
ROE n/a
ROIC -29.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$134.80*
(-14.23% downside)
Low
105
Current: $157.17
High
184
Target: 134.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue18.6634.2931.1815.3536.2530.6620.9222.0814.690.34
Revenue Growth-45.57%9.98%103.06%-57.65%18.24%46.59%-5.26%50.3%4182.22%-
Gross Profit18.6634.2931.1815.3536.2530.6620.927.387.690.34
Operating Income-121-174-172-269-157-83.69-52.43-29.67-21.58-38.49
Net Income-133-185-184-280-157-82.95-51.98-28.51-19.36-35.71
Shares Outstanding24.1018.4914.6313.5413.1111.298.486.595.685.24
Earnings Per Share-5.51-9.99-12.56-20.60-12.00-7.40-6.20-4.40-3.40-6.80
Operating Cash Flow-137-185-144-259-126-67.01-45.36-18.23-23.63-32.85
Capital Expenditures-1.86-1.37-4.19-18.20-18.27-7.23-5.67-4.02-0.61-1.56
Free Cash Flow-138-186-149-277-144-74.24-51.03-22.25-24.24-34.41
Cash & Equivalents82.1810418627026816813445.8518.3131.68
Total Debt3213193183160.401.001.881.210.320.40
Net Cash / Debt-238-215-131-45.9626816713344.6517.9931.28
Assets17320830239438627623510266.5874.84
Liabilities35937640440093.3746.3831.8922.1112.7315.79
Book Value-186-168-102-5.5529323020380.2453.8559.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Novavax, Inc.
Country United States
Employees 165
CEO Stanley C. Erck

Stock Information

Ticker Symbol NVAX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NVAX
IPO Date December 5, 1995

Description

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.